Access Bio, Inc.
Monroe Township, NJ
- UEI
- EZEJBJ28AMV4
- CAGE
- 3CNE1
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 7 Fitzgerald Ave, Monroe Township, NJ 08831, USA
- Website
- accessbio.net
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $340,654,000 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ihealth Labs Inc. | Sunnyvale, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Celltrion USA Inc. | Jersey City, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Sekisui Diagnostics, LLC | San Diego, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Inbios International Inc. | Seattle, WA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Maxim Biomedical, Inc. | Rockville, MD | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Access Bio, Inc. is a consulting group specializing in the development of drug, biologic, and medical device products. They aim to improve the lives and well-being of people worldwide. Access Bio is a corporate entity that is minority owned, for profit, Asian-Pacific American owned, and a manufacturer of goods.
Through past prime federal contract awards, Access Bio has provided COVID-19 tests and related products and services. This includes a $88.7 million definitive contract from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to provide over-the-counter COVID-19 tests from 2023-2025. Additionally, Access Bio was awarded a $46.75 million definitive contract by the same agency to procure over-the-counter COVID-19 tests from March-May 2023. Access Bio also received a $205.2 million firm fixed price delivery order contract from the Defense Logistics Agency Troop Support Medical to supply CareStart COVID-19 antigen tests from December 2022-May 2023. As a subcontractor, Access Bio provided 800 units of G6PD Rapid Diagnostic Test CareStart G6PD to diagnose G6PD deficiency in persons with Malaria.
Access Bio holds an indefinite delivery contract from the Defense Logistics Agency Troop Support Medical to provide COVID-19 related products and services, with a potential value of $410.4 million through November 2023. Under this contract, Access Bio serves as the prime contractor supplying CareStart COVID-19 rapid antigen tests. A $205.2 million firm fixed price delivery order was issued against this contract for Access Bio to provide CareStart COVID-19 antigen tests from December 2022-May 2023 to support COVID-19 testing requirements.
Quick answers
Is Access Bio, Inc. registered in SAM.gov?
Yes. Access Bio, Inc.'s SAM.gov registration is active through December 2, 2026.
How much has Access Bio, Inc. received in federal contracts?
Federal contracts obligated $340,654,000 to Access Bio, Inc. in fiscal years 2023 through 2027.
What is Access Bio, Inc.'s most recent federal award?
Access Bio, Inc.'s most recent federal contract award is Over the counter (OTC) covid-19 tests (75A50223C00035), from Office of the Assistant Secretary for Preparedness and Response, on September 20, 2023.
On GovTribe
See Access Bio, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors